Table 2:

Model performance in estimating the risk of recurrence

Variable	Value (95% CI)
	GSE107943	TCGA	Training cohort	Validation cohort (RNA panel)	Validation cohort (Risk model)
Sensitivity, %	85.0 (62.1–96.8)	69.2 (38.6–90.9)	81.1 (61.7–86.2)	79.8 (71.1–86.9)	85.3 (77.3–91.4)
Specificity, %	87.5 (47.3–99.7)	100.0 (76.8–100.0)	85.2 (79.0–96.8)	70.6 (58.3–81.0)	76.5 (64.6–85.9)
AUC, %	91.9 (75.2–98.8)	90.7 (73.1–98.4)	89.0 (78.7–95.4)	85.5 (79.5–90.4)	88.6 (82.9–92.9)
PPV, %	94.4 (72.9–99.1)	100.0	88.2 (75.0–94.9)	81.3 (74.8–86.4)	85.3 (79.0–90.0)
NPV, %	70.0 (44.3–87.2)	77.8 (58.7–88.2)	76.7 (62.3–86.7)	68.6 (59.3–76.6)	76.5 (67.0–83.9)

AUC, area under the curve; CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value; TCGA, The Cancer Genome Atlas